Author

B. Tarbet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 3 Organism:human· 2 Assay:cryo-EM· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Hurst· 5 shared C. Ma· 3 shared J. Wang· 3 shared Y. Hu· 3 shared J. A. Townsend· 2 shared M. D. Sacco· 2 shared M. T. Marty· 2 shared T. Szeto· 2 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

B. Hurst

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Strain dependent structural effects and in vivo efficacy of enterovirus-D68 inhibitors

T. R. Lane, J. Fu, B. Sherry, B. Tarbet, B. Hurst, O. Riabova, E. Kazakova, A. Egorova, P. Clarke, J. S. Leser, J. Frost, M. Rudy, K. Tyler, T. Klose, R. J. Kuhn, , S. Ekins

This study develops a potent EV-D68 inhibitor, 11526092, showing improved in vitro potency and in vivo efficacy compared to pleconaril, with strain-dependent structural effects observed via cryo-EM.

bioRxiv · Dec 24, 2021 · PreprintPharmacology & Toxicology

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

M. D. Sacco, C. Ma, P. Lagarias, A. Gao, J. A. Townsend, X. Meng, P. Dube, X. Zhang, Y. Hu, N. Kitamura, B. Hurst, B. Tarbet, M. T. Marty, A. Kolocouris, Y. Xiang, , J. Wang

This study determines the structure of SARS-CoV-2 Mpro with calpain inhibitors and analogues, revealing new insights for developing dual inhibitors against Mpro and cathepsin L.

Science Advances · Dec 11, 2020Peer-reviewedBiophysics

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

Y. Hu, C. Ma, T. Szeto, B. Hurst, B. Tarbet, J. Wang

This study identifies four compounds with broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV-2, by inhibiting viral Mpro and cathepsin L.

bioRxiv · Oct 30, 2020Pharmacology & Toxicology

Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases

M. Westberg, Y. Su, X. Zou, L. Ning, B. Hurst, B. Tarbet, M. Lin

The paper designs a new class of protease inhibitors targeting coronavirus Mpro, identifying ML1000 as a potent inhibitor with low-nanomolar affinity and antiviral activity.

bioRxiv · Sep 15, 2020Biochemistry

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

C. Ma, M. D. Sacco, B. Hurst, J. A. Townsend, Y. Hu, T. Szeto, X. Zhang, B. Tarbet, M. T. Marty, Y. Chen, J. Wang

This study identifies inhibitors of SARS-CoV-2 main protease that show potent antiviral activity in cell culture.

Cell Research · Jun 15, 2020Peer-reviewedPharmacology & Toxicology